Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma.
Maurício Fernando Silva Almeida RibeiroLuiza Lara GadottiKarina Perez SacardoCarlos Diego Holanda LopesRodrigo SaddiJoão Victor Machado AlessiMariana Petaccia de MacedoEllen Caroline Toledo do NascimentoLeonardo de Abreu TestagrossaArtur KatzPublished in: SAGE open medical case reports (2022)
Chromosomal rearrangements involving the c-ros oncogene 1 ( ROS1 ) gene define a subset of non-small cell lung cancers highly sensitive to small-molecule tyrosine kinase inhibitors. However, little is known about the impact of different fusion partners on tyrosine kinase inhibitor efficacy. We herein describe a case of a 26-year-old never-smoker patient from southern Africa with metastatic lung adenocarcinoma driven by SLC12A2 - ROS1 fusion, who had a pronounced and durable response to crizotinib. The present case underscores the importance of pursuing actionable alterations in patients with similar clinical and epidemiological characteristics. In addition, provides the second report of crizotinib activity against lung malignancies harboring the unique SLC12A2-ROS1 fusion and highlights the importance of a deeper understanding of molecular alterations in underrepresented subgroups of patients to tailor the decision-making in daily practice.
Keyphrases
- cell death
- reactive oxygen species
- dna damage
- small molecule
- advanced non small cell lung cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- small cell lung cancer
- copy number
- chronic kidney disease
- physical activity
- stem cells
- single cell
- prognostic factors
- gene expression
- genome wide
- quality improvement
- protein protein
- hepatitis c virus
- hiv infected
- bone marrow
- single molecule
- fluorescent probe
- men who have sex with men